GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Recbio Technology Co Ltd (HKSE:02179) » Definitions » Intrinsic Value: Projected FCF

Jiangsu Recbio Technology Co (HKSE:02179) Intrinsic Value: Projected FCF : HK$0.00 (As of Jun. 05, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Recbio Technology Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-05), Jiangsu Recbio Technology Co's Intrinsic Value: Projected FCF is HK$0.00. The stock price of Jiangsu Recbio Technology Co is HK$8.30. Therefore, Jiangsu Recbio Technology Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Jiangsu Recbio Technology Co's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:02179's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.16
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Jiangsu Recbio Technology Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Jiangsu Recbio Technology Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Recbio Technology Co Intrinsic Value: Projected FCF Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Jiangsu Recbio Technology Co's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Jiangsu Recbio Technology Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Recbio Technology Co's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Jiangsu Recbio Technology Co's Price-to-Projected-FCF falls into.


;
;

Jiangsu Recbio Technology Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Jiangsu Recbio Technology Co  (HKSE:02179) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Jiangsu Recbio Technology Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=8.30/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Recbio Technology Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Jiangsu Recbio Technology Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Recbio Technology Co Business Description

Traded in Other Exchanges
Address
No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Executives
Feng Tao 2201 Interest of corporation controlled by you
Bei Jing Jun Lian Cheng Yuan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Zhu Linan 2201 Interest of corporation controlled by you
Jun Lian Zi Ben Guan Li Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Qi Jia Rui Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Jun Cheng He Zhong Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Jun Lian Jie You Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hui Zhi Yi Hao Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
La Sa Jun Qi Qi Ye Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Chao Rui Yi Yao Ke Ji He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Lyfe Capital Fund Iii (dragon), L.p.
Liu Yong
Chen Wei 2201 Interest of corporation controlled by you
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you

Jiangsu Recbio Technology Co Headlines

No Headlines